A Somunkiran1, C T Erel, F Demirci, M L Senturk. 1. Abant Izzet Baysal University, Duzce Medical School, Department of Obstetrics and Gynecology, 81620 Konuralp, Duzce, Turkey. aslisomunkiran@yahoo.com
Abstract
OBJECTIVE: To compare the effectiveness of tibolone and 17beta-estradiol on climacteric symptoms, in a randomized, single-blind, cross-over study in surgically menopausal women. MATERIAL AND METHODS:Forty surgically menopausal women were divided randomly into two groups. Group A received treatment with tibolone for 6 months, while group B received 17beta-estradiol. After 3 weeks washout period, treatment protocols were exchanged for another 6 months. The climacteric symptoms were assessed with Greene Climacteric Scale at baseline, during washout and after the treatments. Statistical analysis was done with the Wilcoxon's Sign Rank test. RESULTS: Both treatments significantly improved the scores of all subscales with respect to baseline. However, the improvement in psychological, somatic and sexual subscales were significantly superior in the tibolone group compared with 17beta-estradiol group. Both treatments showed comparable improvements in the relief of vasomotor symptoms. CONCLUSION: Our findings suggest that tibolone may improve mood, libido and somatic symptoms in surgically menopausal women to a greater extent than estrogen therapy alone.
RCT Entities:
OBJECTIVE: To compare the effectiveness of tibolone and 17beta-estradiol on climacteric symptoms, in a randomized, single-blind, cross-over study in surgically menopausal women. MATERIAL AND METHODS: Forty surgically menopausal women were divided randomly into two groups. Group A received treatment with tibolone for 6 months, while group B received 17beta-estradiol. After 3 weeks washout period, treatment protocols were exchanged for another 6 months. The climacteric symptoms were assessed with Greene Climacteric Scale at baseline, during washout and after the treatments. Statistical analysis was done with the Wilcoxon's Sign Rank test. RESULTS: Both treatments significantly improved the scores of all subscales with respect to baseline. However, the improvement in psychological, somatic and sexual subscales were significantly superior in the tibolone group compared with 17beta-estradiol group. Both treatments showed comparable improvements in the relief of vasomotor symptoms. CONCLUSION: Our findings suggest that tibolone may improve mood, libido and somatic symptoms in surgically menopausal women to a greater extent than estrogen therapy alone.
Authors: Ana Marcia I S Gaudard; Sulani Silva de Souza; Maria E S Puga; Jane Marjoribanks; Edina M K da Silva; Maria R Torloni Journal: Cochrane Database Syst Rev Date: 2016-08-01
Authors: Marina M Reeves; Caroline O Terranova; Jane M Erickson; Jennifer R Job; Denise S K Brookes; Nicole McCarthy; Ingrid J Hickman; Sheleigh P Lawler; Brianna S Fjeldsoe; Genevieve N Healy; Elisabeth A H Winkler; Monika Janda; J Lennert Veerman; Robert S Ware; Johannes B Prins; Theo Vos; Wendy Demark-Wahnefried; Elizabeth G Eakin Journal: BMC Cancer Date: 2016-10-28 Impact factor: 4.430
Authors: Rodolfo Pinto-Almazán; Julia J Segura-Uribe; Eunice D Farfán-García; Christian Guerra-Araiza Journal: Biomed Res Int Date: 2017-01-16 Impact factor: 3.411